GNS Healthcare, Covance to enable more efficient, cost-effective drug development

Friday, September 21, 2012 02:31 PM

GNS Healthcare, a Cambridge, Mass.-based healthcare data analytics company focused on enabling personalized medicine, has entered into a collaboration with global CRO Covance to develop novel data-driven models that will assist pharmaceutical companies in optimizing the efficiency and cost-effectiveness of drug development activities.

Combining GNS's supercomputer-driven REFS (Reverse Engineering and Forward Simulation) big data analytics platform and Covance's data assets derived from its extensive clinical and scientific support of pharmaceutical drug development, the companies will create computer models that predict the likelihood of development success for a drug candidate given available safety and efficacy data across a variety of patient characteristics, across many diseases, starting with type 2 diabetes. Financial terms of the agreement were not disclosed.

"Our collaboration with Covance combines our unique collective resources and capabilities to tackle what has previously been an intractable challenge—improving dismal clinical drug development success rates," said Colin Hill, president, CEO and co-founder of GNS Healthcare. "The predictive computer models arising from our collaboration will address this problem and will in turn lead to better treatment options for patients.”

The collaboration complements GNS' existing work with several major pharmaceutical companies in creating treatment algorithms to match patients to drugs and to discover novel biomarkers from wide-ranging molecular and clinical trial data.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs